Even though these experimental data suggest PCSK9 inhibitors as valuable options in patients with liver cirrhosis, low serum PCSK9 was associated with a higher mortality in patients with end-stage liver disease [24]. This evidence concerns the gene PCSK9 and End Stage Liver Disease.